GuidelineMMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports2023
Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023.
Guideline in MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 3 syntheses or guidelines pooled it, 149 citations in OpenAlex.
- Vaccination of people with solid tumors and diabetes: existing evidence and recommendations. A position statement from a multidisciplinary panel of scientific societies.Journal of endocrinological investigation · 2025Guideline
- Serotype distribution of invasive and non-invasive pneumococcal disease in adults ≥65 years of age following the introduction of 10- and 13-valent pneumococcal conjugate vaccines in infant national immunization programs: a systematic literature review.Frontiers in public health · 2025Pooled it
- Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024.MMWR. Morbidity and mortality weekly report · 2024Guideline
- Pay-it-forward intervention increased pneumococcal vaccine uptake among older adults in China: a randomized controlled trial.BMC medicine · 2026Trial
- Humoral immune response to polyvalent pneumococcal vaccine in healthy participants receiving efgartigimod: a randomized, open-label, placebo-controlled, parallel-group phase 1 trial.Frontiers in immunology · 2026Trial
- Immune persistence of a single dose of 23-valent pneumococcal polysaccharide vaccine: A 6-year follow-up.Human vaccines & immunotherapeutics · 2025Trial
- Pneumococcal vaccination awareness and uptake among high-risk patients attending internal medicine outpatient clinics: A cross-sectional study.Human vaccines & immunotherapeutics · 2026Article
- Pneumococcal vaccination status in critically ill patients: A cross-sectional study.Human vaccines & immunotherapeutics · 2026Article
- Factors associated with pneumococcal vaccine hesitancy and interventions to improve vaccine uptake in older adults: A narrative review using an established conceptual framework.Human vaccines & immunotherapeutics · 2026Review
- Trends in all-cause pneumonia and influenza hospitalization incidence by coding position - a study of US healthcare claims, 2014-2023.Pneumonia (Nathan Qld.) · 2026Article
- Half a century of pneumococcal vaccination in sickle cell disease: Are we winning the battle or losing immunity?Vaccine · 2026Review
- Article
- A multicentre case-control study about effectiveness of pneumococcal vaccination against pneumonia hospitalization in at-risk adults.Pneumonia (Nathan Qld.) · 2026Article
- Adult adherence to multi-dose vaccine schedules: A population-based assessment of guideline concordance.Public health in practice (Oxford, England) · 2026Article
- Review
- Evaluation of a nurse-led pneumococcal vaccination program in a day hospital.BMC health services research · 2026Observational
- Non-pharmacological Management of Fibrosing Interstitial Lung Diseases.Tuberculosis and respiratory diseases · 2026Article
- The Interplay Between Obstructive Sleep Apnea and Respiratory Infections: A Review Article.Thoracic research and practice · 2026Article
- Trends and Disparities in Ischemic Heart Disease and Pneumonia Associated Mortality in the United States: A Population-Based Retrospective Analysis of Death Records From 1999 to 2023.Journal of epidemiology and global health · 2026Article
- What is driving the resurgence and persistence of vaccine-targeted pneumococcal serotypes?-Serotype 19F as the paradigm.PLoS pathogens · 2026Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This report compiles and summarizes all published recommendations from CDC’s Advisory Committee on Immunization Practices (ACIP) for use of pneumococcal vaccines in adults aged ≥19 years in the United States. This report also includes updated and new clinical guidance for implementation from CDC: Before 2021, ACIP recommended 23-valent pneumococcal polysaccharide vaccine (PPSV23) alone (up to 2 doses), or both a single dose of 13-valent pneumococcal conjugate vaccine (PCV13) in combination with 1–3 doses of PPSV23 in series (PCV13 followed by PPSV23), for use in U.S. adults depending on age and underlying risk for pneumococcal disease. In 2021, two new pneumococcal conjugate vaccines (PCVs), a 15-valent and a 20-valent PCV (PCV15 and PCV20), were licensed for use in U.S. adults aged ≥18 years by the Food and Drug Administration: ACIP recommendations specify the use of either PCV20 alone or PCV15 in series with PPSV23 for all adults aged ≥65 years and for adults aged 19–64 years with certain underlying medical conditions or other risk factors who have not received a PCV or whose vaccination history is unknown. In addition, ACIP recommends use of either a single dose of PCV20 or ≥1 dose of PPSV23 for adults who have started their pneumococcal vaccine series with PCV13 but have not received all recommended PPSV23 doses. Shared clinical decision-making is recommended regarding use of a supplemental PCV20 dose for adults aged ≥65 years who have completed their recommended vaccine series with both PCV13 and PPSV23: Updated and new clinical guidance for implementation from CDC includes the recommendation for use of PCV15 or PCV20 for adults who have received PPSV23 but have not received any PCV dose. The report also includes clinical guidance for adults who have received 7-valent PCV (PCV7) only and adults who are hematopoietic stem cell transplant recipients:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.